Lily Wu, M.D., Ph.D.

A physician-scientist, Wu has made significant scientific contributions to the field of cancer research, developing gene therapy and diagnostic imaging approaches for prostate and breast cancers. In an effort to improve therapies for advanced metastatic prostate cancer, Wu has explored molecular engineering of adenoviral vectors to enhance in vivo gene delivery efficiency. 

Recognizing the urgent need for effective therapies, Wu’s recent work has focused on understanding kidney cancer progression and metastasis. Leveraging informative models and advanced molecular imaging, Wu explored the impact of the tumor microenvironment on cancer progression. Her findings revealed the therapeutic benefits of targeting tumor-infiltrating myeloid cells and macrophages in various cancers.

Wu is also investigating metastatic kidney cancer using CRISPR/Cas9 technology. Her findings highlight the critical role of VHL and its downstream pathways in metastasis, revealing a novel mechanism where cooperation between heterogeneous tumor cells drives metastasis. Ongoing research aims to leverage insights from these studies to identify targets for therapies that prevent the lethal metastasis of kidney cancer and many other epithelial solid tumors.